Fate Therapeutics (FATE) Receives $16.17 Average Price Target from Analysts

Shares of Fate Therapeutics (NASDAQ:FATE) have received an average recommendation of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $16.17.

Several research analysts recently commented on FATE shares. Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price for the company in a report on Tuesday, January 9th. ValuEngine raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright lowered shares of Fate Therapeutics from a “buy” rating to a “neutral” rating and set a $12.00 price target on the stock. in a research report on Tuesday, March 6th. BMO Capital Markets upped their price target on shares of Fate Therapeutics from $7.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 6th. Finally, Wells Fargo reaffirmed an “outperform” rating and set a $19.00 price target (up from $10.00) on shares of Fate Therapeutics in a research report on Tuesday, March 6th.

How to Become a New Pot Stock Millionaire

FATE traded down $0.02 during trading hours on Friday, hitting $11.32. 252,480 shares of the company’s stock were exchanged, compared to its average volume of 718,479. Fate Therapeutics has a 1-year low of $2.52 and a 1-year high of $14.45. The stock has a market capitalization of $608.99, a price-to-earnings ratio of -11.10 and a beta of 1.74. The company has a current ratio of 9.29, a quick ratio of 9.29 and a debt-to-equity ratio of 0.19.

Fate Therapeutics (NASDAQ:FATE) last announced its earnings results on Monday, March 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.05). Fate Therapeutics had a negative return on equity of 71.00% and a negative net margin of 1,046.08%. The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.02 million. The business’s revenue for the quarter was up .0% compared to the same quarter last year. research analysts predict that Fate Therapeutics will post -0.94 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Monashee Investment Management LLC bought a new stake in Fate Therapeutics during the fourth quarter worth $1,833,000. 683 Capital Management LLC raised its position in Fate Therapeutics by 25.8% during the fourth quarter. 683 Capital Management LLC now owns 853,800 shares of the biopharmaceutical company’s stock worth $5,217,000 after acquiring an additional 175,000 shares in the last quarter. Neuberger Berman Group LLC raised its position in shares of Fate Therapeutics by 167.6% in the third quarter. Neuberger Berman Group LLC now owns 133,000 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 83,300 shares during the period. J. Goldman & Co LP bought a new position in shares of Fate Therapeutics in the fourth quarter valued at about $1,277,000. Finally, Two Sigma Investments LP bought a new position in shares of Fate Therapeutics in the fourth quarter valued at about $1,043,000. 66.41% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Fate Therapeutics (FATE) Receives $16.17 Average Price Target from Analysts” was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/04/19/fate-therapeutics-fate-receives-16-17-average-price-target-from-analysts.html.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply